Sarepta MOMENTUM Phase 2 clinical trial now recruiting in the UK

We are pleased to announce that Sarepta's Phase 2 MOMENTUM trial is now recruiting in the UK at Alder Hey Children's NHS Foundation Trust.

  • 2 Nov 2020

This phase 2 study is designed to determine the maximum dose for Sarepta Therapeutics Exon 51 skipping therapy, as well as its safety and tolerability.

There will be two arms to the study - in Part A, patients will receive 1 of 5 doses of SRP-5051 monthly by intravenous infusion. Once the maximum dose has be has been determined, all patients will then roll over into Part B and will receive the maximum dose by intravenous infusion for 24 weeks. In Part B, an additional 15 patients will also be enrolled at the beginning of the study. 

The trial is now recruiting in the UK at Alder Hey Children's NHS Foundation Trust.  

The UK sites have not yet been finalised, we will provide an update once we have these detail

For more information about this trial visit the Clinical Trial Finder.

To receive clinical trial updates directly into your inbox, Join the Hub. 

 

We have placed cookies on your computer to help make this website better. For more information please click here

By continuing to use this site or closing this panel, we'll assume you're OK to continue. You can view our full privacy policy here